Hot Takes from Clinical Trials in Lung Disease

Hot Takes from Clinical Trials in Lung Disease

Regular price
Sale price
Sold out
Unit price




CME credits and/or Certificates of Completion are not provided for this session.

You can save 20% today by joining the ATS.Join more than 16,000 healthcare providers and researchers as a member of the American Thoracic Society today. As an ATS member, you’ll gain access to cutting-edge science, collaboration opportunities, discounts on the annual ATS International Conference, and resources to share with patients. The ATS offers multiple ways to get involved, from Assembly membership to in-person networking opportunities, as well as an online community offered through DocMatter. Join the ATS Today!

J. Smith: Improvements in Cough Frequency Over 24 Hours with BLU-5937, a Selective P2X3 Antagonist, in Patient Subgroups Defined by Baseline Awake Cough Frequencies

K. B. Newman: Safety and Tolerability Demonstrated with Inhaled αENaC Antisense Oligonucleotide (ION-827359) in Patients with Cystic Fibrosis

F. Conway: Targeted Lung Denervation for Chronic Obstructive Pulmonary Disease: 12-Month Crossover Data from the AIRFLOW-2 Trial

P. Lenga: Endoscopic Lung Volume Reduction with Endobronchial Valves in Patients with Hypercapnia: Results of a Prospective Observational Clinical Study

D. Slebos: Long-Term Follow-up of Severe Emphysema Patients Treated with Zephyr Valves in the Multicenter, Randomized TRANSFORM Study

M. D. Roth: Combination Therapy Trials for Scleroderma-Related Interstitial Lung Disease: Initial and Adaptive Trial Aspects of Scleroderma Lung Study III in the Setting of a Rapidly Changing Clinical Environment

D. Khanna: Tocilizumab in Systemic Sclerosis Interstitial Lung Disease: Safety and Efficacy in the Double-Blind and Open-Label Periods of a Randomized Controlled Phase 3 Trial

C. J. Ryerson: Effect of Nintedanib on Decline in Forced Vital Capacity (FVC) in Patients with Progressive Fibrosing Interstitial Lung Diseases (ILDs) by GAP Stage

S. D. Nathan: Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension Due to Parenchymal Lung Disease in the INCREASE Trial